• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Protection for pacemakers

Bioengineer by Bioengineer
November 21, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Hylomorph


ETH scientists have developed a special protective membrane made of cellulose that significantly reduces the build-up of fibrotic tissue around cardiac pacemaker implants, as reported in the current issue of the journal Biomaterials. Their development could greatly simplify surgical procedures for patients with cardiac pacemakers.

“Every pacemaker has to be replaced at some point. When this time comes, typically after about five years when the device’s battery expires, the patient has to undergo surgery,” explains Aldo Ferrari, Senior Scientist in ETH Professor Dimos Poulikakos’s group and at Empa. “If too much fibrotic tissue has formed around the pacemaker, it complicates the procedure,” he explains. In such cases, the surgeon has to cut into and remove this excess tissue. Not only does that prolong the operation, it also increases the risk of complications such as infection.

Microstructure reduces fibrotic tissue formation

To overcome this issue, Ferrari and his colleagues at ETH Zurich spent the last few years developing a membrane with a special surface structure that is less conducive to the growth of fibrotic tissue than the smooth metal surface of pacemakers. This membrane has now been patented and Ferrari is working with fellow researchers at the Wyss Zurich research center, the University of Zurich and the German Center of Cardiovascular Research in Berlin to make it market-ready for use in patients.

As part of this process, the research consortium has now tested the membrane on pigs. In each pig, the scientists implanted two pacemakers, one of which was enveloped in the cellulose membrane.

Following the one-year test period, the researchers can report positive results: the pigs’ bodies tolerate the membrane and do not reject it. “This is an important finding because tolerance is a core requirement for implant materials,” Ferrari says. Just as importantly, the membrane did what it was supposed to: the fibrotic tissue that formed around it was, on average, only a third as thick as the tissue that formed around the unencapsulated pacemakers.

Next step: Clinical trials

The scientists attribute this reduction in fibrotic tissue formation in the first stage to the material itself – cellulose is fibrous by nature. “When fibrotic tissue forms, the first stage is the deposition of proteins on the surface. A fibrous membrane surface impedes this process,” explains Francesco Robotti, lead author of the study and a scientist in ETH Professor Poulikakos’s group. Another factor is that the researchers created the membrane with honeycomb-like indentations in the surface, each measuring 10 micrometres in diameter. “These indentations make it difficult for the cells that form fibrotic tissue to adhere to the surface – the second stage in the formation processes,” Robotti says.

Now that the material has proved successful in animal trials, the scientists plan to apply for approval for clinical trials in humans in partnership with the ETH spin-off Hylomorph, which will be responsible for commercialisation of the membrane. The trials are slated to start next year at three large cardiac centres in Germany.

###

This work was carried out as part of University Medicine Zurich’s flagship Zurich Heart project and ETH+ project ETHeart.

Reference

Robotti F, Sterner I, Bottan S, Monné Rodríguez JM, Pellegrini G, Schmidt T, Falk V, Poulikakos D, Ferrari A, Starck C: Microengineered biosynthesized cellulose as anti-fibrotic in vivo protection for cardiac implantable electronic devices, Biomaterials 2019, 229: 119583, doi: 10.1016/j.biomaterials.2019.119583

Media Contact
Francesco Robotti
robottif@ethz.ch
41-786-418-079

Original Source

https://ethz.ch/en/news-and-events/eth-news/news/2019/11/protection-for-pacemakers.html

Related Journal Article

http://dx.doi.org/10.1016/j.biomaterials.2019.119583

Tags: Biomedical/Environmental/Chemical EngineeringCardiologyChemistry/Physics/Materials SciencesMaterialsMedicine/HealthTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Leisure Sport Study Reveals Distinct Dimension Specific Ties to Life Satisfaction

Leisure Sport Study Reveals Distinct Dimension Specific Ties to Life Satisfaction

November 21, 2026
Prostate Cancer Drug Safety Analysis Reveals Divergent Fall Reporting Signals in FDA Database

Prostate Cancer Drug Safety Analysis Reveals Divergent Fall Reporting Signals in FDA Database

November 21, 2026

Inpatient Claim Models Reveal Tiered Deductible Benchmarks for Medical Insurance Pooling

November 21, 2026

Adolescent Physical Activity Review Maps Eleven Psychological Mediators of Self-Injury

November 21, 2026
Please login to join discussion

POPULAR NEWS

  • Phase I Trial of Novel Antibody-Drug Conjugate Shows Early Efficacy in Sarcoma

    Phase I Trial of Novel Antibody-Drug Conjugate Shows Early Efficacy in Sarcoma

    29 shares
    Share 12 Tweet 7
  • New Unified Contraction Framework Establishes Fixed Point Results in Metric Spaces

    29 shares
    Share 12 Tweet 7
  • Early Skin Molecular Signatures Predict Atopic Dermatitis Risk in Asian Infant Cohort

    29 shares
    Share 12 Tweet 7
  • Review Finds Minor Cannabinoids Lack Established Clinical Efficacy for ADHD Treatment

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leisure Sport Study Reveals Distinct Dimension Specific Ties to Life Satisfaction

Prostate Cancer Drug Safety Analysis Reveals Divergent Fall Reporting Signals in FDA Database

Inpatient Claim Models Reveal Tiered Deductible Benchmarks for Medical Insurance Pooling

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.